RS51519B - HYINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF PERIPHERAL ARTERIAL DISEASES AND AS PHOSPHODIESTERASE INHIBITORS - Google Patents

HYINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF PERIPHERAL ARTERIAL DISEASES AND AS PHOSPHODIESTERASE INHIBITORS

Info

Publication number
RS51519B
RS51519B RSP-2010/0523A RSP20100523A RS51519B RS 51519 B RS51519 B RS 51519B RS P20100523 A RSP20100523 A RS P20100523A RS 51519 B RS51519 B RS 51519B
Authority
RS
Serbia
Prior art keywords
treatment
peripheral arterial
arterial disease
phosphodiesterase inhibitors
derivatives useful
Prior art date
Application number
RSP-2010/0523A
Other languages
English (en)
Serbian (sr)
Inventor
Richard Franklin
Original Assignee
Shire Biopharmaceuticals Holdings Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Biopharmaceuticals Holdings Ireland Limited filed Critical Shire Biopharmaceuticals Holdings Ireland Limited
Publication of RS51519B publication Critical patent/RS51519B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RSP-2010/0523A 2004-08-04 2005-08-04 HYINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF PERIPHERAL ARTERIAL DISEASES AND AS PHOSPHODIESTERASE INHIBITORS RS51519B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59843204P 2004-08-04 2004-08-04

Publications (1)

Publication Number Publication Date
RS51519B true RS51519B (en) 2011-06-30

Family

ID=35839972

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2010/0523A RS51519B (en) 2004-08-04 2005-08-04 HYINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF PERIPHERAL ARTERIAL DISEASES AND AS PHOSPHODIESTERASE INHIBITORS

Country Status (22)

Country Link
US (1) US20060030574A1 (zh)
EP (2) EP1949893B1 (zh)
JP (1) JP4758993B2 (zh)
CN (1) CN101014344A (zh)
AT (1) ATE484278T1 (zh)
AU (1) AU2005271275A1 (zh)
BR (1) BRPI0513943A (zh)
CA (1) CA2575512C (zh)
CY (1) CY1110881T1 (zh)
DE (1) DE602005024192D1 (zh)
DK (1) DK1949893T3 (zh)
EA (1) EA200700406A1 (zh)
ES (1) ES2353848T3 (zh)
HR (1) HRP20100681T1 (zh)
MX (1) MX2007001513A (zh)
NO (1) NO20071098L (zh)
PL (1) PL1949893T3 (zh)
PT (1) PT1949893E (zh)
RS (1) RS51519B (zh)
SI (1) SI1949893T1 (zh)
WO (1) WO2006017823A2 (zh)
ZA (1) ZA200701850B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
GB0623750D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808952D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2732403A (en) * 1956-01-24 Chclj
US2862966A (en) * 1958-12-02 archo
US1947926A (en) * 1934-02-20 Seed grain dressings and process of
US2256999A (en) * 1939-03-08 1941-09-23 Du Pont Nitration of organic compounds
US2469695A (en) * 1946-02-02 1949-05-10 Eastman Kodak Co Nitroaminobenzene ester compounds
US2608584A (en) * 1947-03-19 1952-08-26 Nopco Chem Co Preparation of n-alkyl arylamines
US2883435A (en) * 1956-10-10 1959-04-21 Gen Aniline & Film Corp Purification of 1,2-dichloro-4-nitrobenzene
US3313854A (en) * 1961-11-20 1967-04-11 Universal Oil Prod Co Preparation of para-nitrodiphenylamines utilizing a copper oxide catalyst
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
JPS49132019A (zh) * 1973-02-26 1974-12-18
DE2400887A1 (de) * 1974-01-09 1975-08-28 Bayer Ag Verfahren zur herstellung von nitroderivaten aromatischer verbindungen
JPS5752352B2 (zh) * 1974-02-28 1982-11-06
US3983119A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3983120A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
JPS5251379A (en) * 1975-10-24 1977-04-25 Sumitomo Chem Co Ltd Preparation 3,4-dihydro-2(1h)-quinazoline derivates
JPS5291885A (en) * 1976-01-23 1977-08-02 Sumitomo Chem Co Ltd 3,4-dihydro-2(1h)-quinazolinone derivatives
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4208521A (en) * 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
EP0028489B1 (en) * 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
ZW16481A1 (en) * 1980-08-15 1982-03-10 Hoffmann La Roche Novel imidazoquinazoline derivatives
US4357330A (en) * 1981-07-30 1982-11-02 Bristol-Myers Company Pharmaceutical compositions
US4444777A (en) * 1981-07-30 1984-04-24 Bristol-Myers Company Pharmaceutical compositions of anagrelide and sulfinpyrazone
US4455311A (en) * 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4847276A (en) * 1988-09-06 1989-07-11 Merrell Dow Pharmaceuticals Inc. Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione
GB8824496D0 (en) * 1988-10-19 1988-11-23 Beecham Group Plc Process
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
US5043327A (en) * 1989-07-18 1991-08-27 Janssen Pharmaceutica N.V. Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use
US5391737A (en) * 1991-05-22 1995-02-21 Egis Gyogyszergyar Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
US6024975A (en) * 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
CA2265495A1 (en) * 1996-09-13 1998-03-19 The Board Of Trustees Of The Leland Stanford Junior University Non-hormonal method of contraception
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1999020223A2 (en) * 1997-10-20 1999-04-29 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6156753A (en) * 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
WO2001021259A2 (en) * 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
US6194420B1 (en) * 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US6388073B1 (en) * 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US20030235609A1 (en) * 2002-01-25 2003-12-25 Lautt Wilfred Wayne Use of cholinesterase antagonists to treat insulin resistance
US20030114673A1 (en) * 2002-05-29 2003-06-19 Lang Philip C. 2-amino-5,6-dihalo-3,4-dihydroquinazolines with blood platelet reducing properties
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR20050111317A (ko) * 2003-01-23 2005-11-24 샤이어 홀딩스 아게 혈소판혈병의 치료를 위한 제형 및 방법
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases

Also Published As

Publication number Publication date
WO2006017823A3 (en) 2006-05-04
CN101014344A (zh) 2007-08-08
CA2575512C (en) 2010-12-14
JP2008509163A (ja) 2008-03-27
CA2575512A1 (en) 2006-02-16
PT1949893E (pt) 2011-01-04
AU2005271275A1 (en) 2006-02-16
EA200700406A1 (ru) 2007-08-31
EP1949893A3 (en) 2008-08-20
EP1778235A2 (en) 2007-05-02
EP1778235A4 (en) 2008-08-20
ZA200701850B (en) 2008-08-27
US20060030574A1 (en) 2006-02-09
PL1949893T3 (pl) 2011-04-29
DE602005024192D1 (de) 2010-11-25
EP1949893B1 (en) 2010-10-13
SI1949893T1 (sl) 2011-02-28
MX2007001513A (es) 2007-03-27
CY1110881T1 (el) 2015-06-10
JP4758993B2 (ja) 2011-08-31
NO20071098L (no) 2007-05-03
EP1949893A2 (en) 2008-07-30
ES2353848T3 (es) 2011-03-07
HRP20100681T1 (hr) 2011-01-31
DK1949893T3 (da) 2011-01-31
WO2006017823A2 (en) 2006-02-16
ATE484278T1 (de) 2010-10-15
BRPI0513943A (pt) 2008-05-20

Similar Documents

Publication Publication Date Title
ZA200701850B (en) Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
NO2007010I1 (no) Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt
BRPI0416628A (pt) uso de compostos orgánicos
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
AR087241A2 (es) Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
WO2007075695A3 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
MXPA04000793A (es) Novedoso metodo terapeutico.
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
MXPA06013039A (es) El tratamiento de enfermedad respiratoria.
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
ATE547104T1 (de) Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen
WO2007095609A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder
WO2003053352A3 (en) Therapeutic compounds for treating dyslipidemic conditions
WO2004053107A3 (en) Methods for treating diabetes
TW200605893A (en) Use of organic compounds
DE60206391D1 (de) Verwendung von thiazolderivaten zur herstellung eines medikaments zur behandlung von chronischen obstruktiven atemwegserkrankungen
UA95094C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства